Schiff R - Search Results

1

Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer.

Guarducci C, Bonechi M, Benelli M, Biagioni C, Boccalini G, Romagnoli D, Verardo R, Schiff R, Osborne CK, De Angelis C, Di Leo A, Malorni L, Migliaccio I. Guarducci C, et al. Among authors: schiff r. NPJ Breast Cancer. 2018 Nov 28;4:38. doi: 10.1038/s41523-018-0092-4. eCollection 2018. NPJ Breast Cancer. 2018. PMID: 30511015 Free PMC article.

2

Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo.

Schiff R, Reddy P, Ahotupa M, Coronado-Heinsohn E, Grim M, Hilsenbeck SG, Lawrence R, Deneke S, Herrera R, Chamness GC, Fuqua SA, Brown PH, Osborne CK. Schiff R, et al. J Natl Cancer Inst. 2000 Dec 6;92(23):1926-34. doi: 10.1093/jnci/92.23.1926. J Natl Cancer Inst. 2000. PMID: 11106684

3

Estrogen receptor: current understanding of its activation and modulation.

Osborne CK, Schiff R, Fuqua SA, Shou J. Osborne CK, et al. Among authors: schiff r. Clin Cancer Res. 2001 Dec;7(12 Suppl):4338s-4342s; discussion 4411s-4412s. Clin Cancer Res. 2001. PMID: 11916222 Review.

4

Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth.

Liu Y, Ludes-Meyers J, Zhang Y, Munoz-Medellin D, Kim HT, Lu C, Ge G, Schiff R, Hilsenbeck SG, Osborne CK, Brown PH. Liu Y, et al. Among authors: schiff r. Oncogene. 2002 Oct 31;21(50):7680-9. doi: 10.1038/sj.onc.1205883. Oncogene. 2002. PMID: 12400010

5

Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response.

Schiff R, Massarweh S, Shou J, Osborne CK. Schiff R, et al. Clin Cancer Res. 2003 Jan;9(1 Pt 2):447S-54S. Clin Cancer Res. 2003. PMID: 12538499 Review.

6

Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer.

Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA, Wong J, Allred DC, Clark GM, Schiff R. Osborne CK, et al. Among authors: schiff r. J Natl Cancer Inst. 2003 Mar 5;95(5):353-61. doi: 10.1093/jnci/95.5.353. J Natl Cancer Inst. 2003. PMID: 12618500

7

Dominant-negative nuclear receptor corepressor relieves transcriptional inhibition of retinoic acid receptor but does not alter the agonist/antagonist activities of the tamoxifen-bound estrogen receptor.

Morrison AJ, Herrera RE, Heinsohn EC, Schiff R, Osborne CK. Morrison AJ, et al. Among authors: schiff r. Mol Endocrinol. 2003 Aug;17(8):1543-54. doi: 10.1210/me.2001-0144. Epub 2003 May 1. Mol Endocrinol. 2003. PMID: 12730327

8

Estrogen receptor beta protein in human breast cancer: correlation with clinical tumor parameters.

Fuqua SA, Schiff R, Parra I, Moore JT, Mohsin SK, Osborne CK, Clark GM, Allred DC. Fuqua SA, et al. Among authors: schiff r. Cancer Res. 2003 May 15;63(10):2434-9. Cancer Res. 2003. PMID: 12750263 Free PMC article.

9

Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer.

Osborne CK, Schiff R. Osborne CK, et al. Among authors: schiff r. Breast. 2003 Dec;12(6):362-7. doi: 10.1016/s0960-9776(03)00137-1. Breast. 2003. PMID: 14659106 Review.

10

Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance.

Schiff R, Massarweh SA, Shou J, Bharwani L, Mohsin SK, Osborne CK. Schiff R, et al. Clin Cancer Res. 2004 Jan 1;10(1 Pt 2):331S-6S. doi: 10.1158/1078-0432.ccr-031212. Clin Cancer Res. 2004. PMID: 14734488

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

370 results

Search Page